Our Webinars

Our Webinars

The Ever-Increasing Impact of Gene Therapy in Rare Oncology Trials

The Ever-Increasing Impact of Gene Therapy in Rare Oncology Trials

Date: Monday, November 18, 2019
Time: 11am EST(NA) / 4pm GMT (UK) / 5pm CET (EU-Central)
Length: 60 minutes

REGISTER

The alteration of genetic material held within a person’s cells as a way of treating or preventing disease is the simple, common definition of gene therapy. This type of therapy is rapidly progressing within the world of oncology, for both treatment and prevention of cancers. However, the future of gene therapy presents some unique questions and challenges. Are we heading in the right direction? What are the ethical considerations? And how do we ensure access to these therapies?

As oncology trials become more complex, scientists are finding that the oncogenic drivers of disease are crafting more discrete patient populations and are therefore turning what was once a very generalized disease state into a rare indication. Now, we are not only working with oncogenic drivers, but also the very genetic code that makes each of us the same, yet different. The impact that oncogenic drivers have on our ability to define a population and ensure equal access to treatment is becoming more critical.

Join this free webinar to hear a discussion about these challenges , with strategies and real-life solutions to support patients, sites and sponsors.

Presenters:



x

Synteract Rare and Orphan Diseases Clinical Trial Leadership

Derek Ansel
Director, Rare and Orphan Diseases

  • 8+ years of clinical laboratory research, monitoring, and project management across Phase I-IV drug development.
  • Broad therapeutic experience in rare disease including pediatric pulmonary atrial hypertension, hemophilia A & B, von Willebrand disease, thrombotic thrombocytopenic purpura, eosinophilic esophagitis, and more.
  • Provides rare disease, gene and cell therapy expertise as an Institutional Review Board member at the Thomas Jefferson University in Philadelphia, PA.
  • Four-time US PharmaTimes Clinical Researcher of the Year finalist and currently pursuing a master’s degree in pharmacology and toxicology from Michigan State University.
Contact us to find out more about our Rare and Orphan Diseases expertise and experience
x

Synteract Oncology Clinical Trial Leadership

Christopher Heckman
VP Oncology Development

With 23 years of clinical research experience, Christopher Heckman is a visionary leader with management, clinical and business development experience. He possesses a broad experience base across the drug development lifecycle, with both strategic and operational lines of responsibility, with hands-on engagement in all development phases as well as global registration experience. Previously, he has held executive director positions at both Celerion and PPD, and was senior director for portfolio management with Parexel International.

Contact us to find out more about our Oncology expertise and experience
Looking for a previous webinar? Go to our Webinars Archive arrow
x

Submit RFI / RFP

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

Contact Synteract

Tell us how to stay in touch with you:

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

Synteract General Medicince Clinical Trial Leadership

Linda RawlingsContact us to find out more about our General Medicine expertise and experience

Linda Rawlings, MSc, FIBMS
VP General Medicine

Contact us to find out more about our General Medicine expertise and experience
x

Synteract Rare and Orphan Diseases Clinical Trial Leadership

Lisa DilworthContact us to find out more about our Rare and Orphan Diseases expertise and experience

Lisa Dilworth
VP Rare and Orphan Diseases

Contact us to find out more about our Rare and Orphan Diseases expertise and experience
x

 

x

Download Resource

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required

x

To complete your download, please choose an option in the Internet Explorer pop-up window at the bottom of this browser.

x

Opt In

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required